Evidence map›Paper›PMID 32354938›Full record

ArticleIn vivo (Athens, Greece)

Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study.

Vitaliana DE Sanctis, Alice DI Rocco, Maria Christina Cox, Maurizio Valeriani, Francesca Perrone Congedi, Dimitri Anzellini, Maria Massaro, Gianluca Vullo, Giuseppe Facondo, Flavia DE Giacomo and 7 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Vitaliana DE SanctisRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Alice DI RoccoDepartment of Translational and Precision Medicine, Hematology Institute, Sapienza University of Rome, Rome, Italy.
Maria Christina CoxHematology Institute, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Maurizio ValerianiRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Francesca Perrone CongediRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Dimitri AnzelliniRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Maria MassaroRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Gianluca VulloRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy gianluca.vullo@uniroma1.it.
Giuseppe FacondoRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Flavia DE GiacomoRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Marco AlfòDepartment of Statistical Sciences, Sapienza University of Rome, Rome, Italy.
Daniela ProsperiNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Sapienza University of Rome, Rome, Italy.
Patrizia PizzichiniNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Sapienza University of Rome, Rome, Italy.
Sabrina PellicciaHematology Institute, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Agostino TafuriHematology Institute, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Maurizio MartelliDepartment of Translational and Precision Medicine, Hematology Institute, Sapienza University of Rome, Rome, Italy.
Mattia Falchetto OstiRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the efficacy of residual site radiation therapy (RSRT) on local control (LC), progression-free (PFS) and overall (OS) survival in patients with primary mediastinal lymphoma (PMBCL), following rituximab and chemotherapy treatment (ICHT). PATIENTS AND

methodsThe study included 34 patients with PMBCL treated between 2006 and 2014 with ICHT with/without autologous stem cell transplantation and RSRT. Between the end of ICHT/stem cell transplantation and RSRT, patients were evaluated with

resultsAll patients received RSRT with a median dose of 30 Gy. Median follow-up was 82 months. One patient out of 34 (3%) showed progressive disease 9 months from diagnosis. The 10-year PFS and OS were 97% and 97% respectively.

conclusionRSRT in patients with PMBCL treated with ICHT did not impact unfavorably on LC and patient survival.

Indexed as

AdolescentAdultAgedAntineoplastic Agents, ImmunologicalFemaleFluorodeoxyglucose F18HumansLymphoma, B-CellMaleMediastinal NeoplasmsMiddle AgedNeoplasm, ResidualNeoplasm StagingPositron-Emission TomographyRetreatmentRetrospective StudiesAntineoplastic Agents, ImmunologicalFluorodeoxyglucose F18hematologyMediastinal lymphomaradiotherapytarget volume

Identifiers

PMID32354938
PMCPMC7279787
OpenAlexW3020843637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.